Abstract: As described below, disclosed herein are methods of analyzing DNA methylation in cell-free DNA (cfDNA) and genomic DNA (gDNA) from sequencing data.

Abstract: Disclosed herein are novel 5? UTR sequences that can be used to control gene expression in various contexts. Also disclosed herein are methods of engineering 5? UTR sequences and methods and kits for screening 5? UTR sequences for a property of interest.

Abstract: As described below, disclosed herein are methods of analyzing DNA methylation in cell-free DNA (cfDNA) and genomic DNA (gDNA) from sequencing data.

Abstract: Described herein are a secure system for sharing private data and related systems and methods for incentivizing and validating private data sharing. In some embodiments, private data providers may register to selectively share private data under controlled sharing conditions. The private data may be cryptographically secured using encryption information corresponding to one or more secure execution environments. To demonstrate to the private data providers that the secure execution environment is secure and trustworthy, attestations demonstrating the security of the secure execution environment may be stored in a distributed ledger (e.g., a public blockchain). Private data users that want access to shared private data may publish applications for operating on the private data to a secure execution environment and publish, in a distributed ledger, an indication that the application is available to receive private data.

Abstract: An ALS treatment method includes administering to an ALS patient an inhibitor for a target A or a promoter for a target B. The target A is one or more genes selected from the genes in Table 1-1 or a protein encoded by the gene, and the inhibitor for the target A is a substance that inhibits expression of the gene, or a substance that inhibits a function of the protein encoded by the gene. The target B is one or more genes selected from the genes in Table 1-2 or a protein encoded by the gene, and the promoter for the target B is a substance that promotes the expression of the gene, or a substance that promotes a function of the protein encoded by the gene.

Abstract: The present disclosure provides methods of inhibiting amyloid synthesis in a subject using cyclodextrin and analogs thereof. Small molecules (cyclodextrin) reverse APOE4-associated cholesterol phenotypes and lead to significantly improved myelination both human in vitro cultures and APOE4 targeted replacement mice. This demonstrates that APOE4 alters cholesterol synthesis and transport in oligodendrocytes which impairs myelination. Collectively, this work uncovers a pathogenic role of APOE4 in oligodendrocytes and myelination and enables therapeutic opportunities for Alzheimer's Disease.

Abstract: Embodiments disclosed herein provide a general, scalable, high-throughput, and high-resolution approach for experimental dissection of regulatory regions and driver nucleotides in the context of human biology and disease. Applicants present HiDRA, a novel high-resolution global screen for transcriptional regulatory activity in accessible chromatin regions, enabling high-efficiency, high-throughput, and high-resolution inference of regulatory activity.

Abstract: Provided herein is a pathway for adipocyte energy consumption regulation involving ARID5B, genetic variant rs1421085, IRX3, and IRX5. Compositions and methods for modulating the pathway in vitro and in vivo for anti-cachectic and anti-obesity effects are provided. Methods of identifying subjects at risk of developing a disorder mediated by a dysregulation of the energy consumption pathway are also provided.

Abstract: Described herein are a secure system for sharing private data and related systems and methods for incentivizing and validating private data sharing. In some embodiments, private data providers may register to selectively share private data under controlled sharing conditions. The private data may be cryptographically secured using encryption information corresponding to one or more secure execution environments. To demonstrate to the private data providers that the secure execution environment is secure and trustworthy, attestations demonstrating the security of the secure execution environment may be stored in a distributed ledger (e.g., a public blockchain). Private data users that want access to shared private data may publish applications for operating on the private data to a secure execution environment and publish, in a distributed ledger, an indication that the application is available to receive private data.

Abstract: Disclosed herein are novel 5? UTR sequences that can be used to control gene expression in various contexts. Also disclosed herein are methods of engineering 5? UTR sequences and methods and kits for screening 5? UTR sequences for a property of interest.

Abstract: Disclosed is a method of determining regulatory activity of nucleotides in a genome, which includes: (1) designating a reference region of the genome; (2) designating a plurality of reporter tiles covering the reference region, where each reporter tile has a length L, the reporter tiles are offset from one another within the reference region with a step sizes, and a ratio of s to L is 1:5 or less; and (3) generating a plurality of reporter constructs corresponding to the reporter tiles.

Abstract: As described below, disclosed herein are methods of analyzing DNA methylation in cell-free DNA (cfDNA) and genomic DNA (gDNA) from sequencing data.

Abstract: Provided herein is a pathway for adipocyte energy consumption regulation involving ARID5B, genetic variant rs1421085, IRX3, and IRX5. Compositions and methods for modulating the pathway in vitro and in vivo for anti-cachectic and anti-obesity effects are provided. Methods of identifying subjects at risk of developing a disorder mediated by a dysregulation of the energy consumption pathway are also provided.